| 49093-8 |
Arbovirus Ab.IgG & IgM panel |
- |
Ser |
Pt |
- |
IF |
|
ACTIVE |
Arbovirus IgG and IgM panel - Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
49093-8 |
|
IF |
|
|
Order |
|
|
|
0 |
Arbovirus IgG+IgM Pnl Ser IF |
|
|
|
N |
|
ACIF; Anticomplement Immunofluorescence; Arbo virus; Arbovirus IgG+IgM Pnl; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Random; Serum; SR; Time Resolved Fluorescence; TRF |
2.42 |
2.21 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 49094-6 |
Arbovirus Ab.IgG & IgM panel |
- |
CSF |
Pt |
- |
IF |
|
ACTIVE |
Arbovirus IgG and IgM panel - Cerebral spinal fluid by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
49094-6 |
|
IF |
|
|
Order |
|
|
|
0 |
Arbovirus IgG+IgM Pnl CSF IF |
|
|
|
N |
|
ACIF; Anticomplement Immunofluorescence; Arbo virus; Arbovirus IgG+IgM Pnl; Cerebral spinal fluid; Cerebrospinal Fl; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; TRF |
2.42 |
2.21 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 49095-3 |
Saint Louis encephalitis virus Ab.IgG & IgM |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Saint Louis encephalitis virus IgG and IgM [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49095-3 |
|
|
|
|
Observation |
|
|
|
0 |
SLEV IgG+IgM Ser-Imp |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Enc; Enceph; Encephalomyelitis; ID; IgG+IgM; Immune globulin G; Immune globulin M; Immunoglobulin G; Immunoglobulin M; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; Microbiology; Nominal; Point in time; Random; Serum; SLE virus; SLEV; SR; St Louis |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49096-1 |
Chlamydia trachomatis DNA |
ACnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Chlamydia trachomatis DNA [Units/volume] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49096-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C trach DNA Spec NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; C trac; C trach; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; LGV; Ligase chain reaction; Ligation-activated transcription; Lymphogranuloma venereum; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Trachoma; Transcription mediated amplification; Unspecified; Viral load |
2.73 |
2.21 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 49097-9 |
Creatine |
MCnc |
Urine |
24H |
Qn |
|
|
ACTIVE |
Creatine [Mass/volume] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
49097-9 |
|
|
|
|
Both |
|
|
|
0 |
Creatine 24h Ur-mCnc |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Level; Mass concentration; QNT; Quan; Quant; Quantitative; UA; UR; Urn |
2.73 |
2.21 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 49098-7 |
Cryptococcus neoformans rRNA |
ACnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Cryptococcus neoformans rRNA [Units/volume] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49098-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
C neoform rRNA Spec NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; C neoform; C neoformans; Crypt; Crypto; Cryptococcal; Cryptococcosis; Cryptococcosus; DNA NUCLEIC ACID PROBE; DNA probe; Gen-Probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; ribosomal RNA; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral load |
2.73 |
2.21 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 49099-5 |
Gadus morhua Ab.IgG |
MCnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Codfish IgG Ab [Mass/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
ALLERGY |
|
49099-5 |
|
|
|
|
Both |
|
|
|
0 |
Codfish IgG-mCnc |
|
|
|
N |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cod; Codfish; f003; f3; Fish; Immune globulin G; Immunoglobulin G; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrod; Serum; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 491-1 |
Temocillin |
Susc |
Isolate |
Pt |
Qn |
MLC |
|
ACTIVE |
Temocillin [Susceptibility] by Minimum lethal concentration (MLC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
491-1 |
|
MLC |
|
|
Observation |
|
|
|
0 |
Temocillin Islt MLC |
|
|
|
Y |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; MBC; Minimum bactericidal concentration; Minimum lethal concentration; Nagaban; Point in time; QNT; Quan; Quant; Quantitative; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Temopen |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 4910-6 |
HLA-Dw5 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-Dw5 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4910-6 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-Dw5 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49100-1 |
H2a-H2b DNA Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
H2a-H2b DNA IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
49100-1 |
|
|
|
|
Both |
|
|
|
0 |
H2a-H2b DNA IgG Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Deoxyribonucleic acid; Drug induced systemic lupus erythematosus; Histone DNA complex ab IgG; Immune globulin G; Immunoglobulin G; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49101-9 |
Helicobacter pylori DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Helicobacter pylori DNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49101-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
H pylori DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C pylori; Campylobacter pylori; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Gastro; Gastroenterology; GI; H pyl; H pylori; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49102-7 |
Herpes virus 8 DNA |
ACnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Herpes virus 8 DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49102-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HHV8 DNA SerPl NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herpesvirus; HHV; HHV8; HHV-8; Human herpes virus; ID; Infectious Disease; InfectiousDisease; Kaposi's Sarcoma-Associated Herpesvirus; KSHV; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.73 |
2.21 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 49103-5 |
Leukocyte casts |
Naric |
Urine sed |
Pt |
Qn |
Microscopy.light.HPF |
|
ACTIVE |
WBC casts [#/area] in Urine sediment by Microscopy high power field |
|
MIN |
DefinitionDescription |
|
|
/HPF |
|
|
|
|
|
|
UA |
|
49103-5 |
|
Microscopy.light.HPF |
|
|
Observation |
|
|
|
0 |
WBC Casts #/area UrnS HPF |
|
|
|
N |
|
#/area; Cast; Kidney; Leuc; Leuk; Leukocytes; Lkcs; LM; Micro; Micros; Microscopic; Nephrology; Number areic; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS; WBC; WBC Casts; WBCs; White blood cell; White blood cells |
2.73 |
2.21 |
|
|
|
|
|
|
|
/[HPF] |
|
|
|
0 |
| 49104-3 |
Mycoplasma pneumoniae DNA |
ACnc |
Bld |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Mycoplasma pneumoniae DNA [Units/volume] in Blood by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49104-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
M pneumo DNA Bld NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Enzootic pneumonia; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; M pneumo; M pneumonia; M pneumoniae; Microbiology; Myco; Myco pneu; Mycoplas; Mycoplasm; Mycoplasmoides pneumoniae; Mycoplasmosis; Mycoplsm; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Pneu; pneum; Pneumo; Pneumon; Pneumonia; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load; WB; Whole blood |
2.73 |
2.21 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 49105-0 |
Phenolphthalein |
MCnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
Phenolphthalein [Mass/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
49105-0 |
|
|
|
|
Both |
|
|
|
0 |
Phenolphthalein Spec-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Other; Phenolthalein; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49106-8 |
Phenols |
MCnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
Phenols [Mass/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
DRUG/TOX |
|
49106-8 |
|
|
|
|
Both |
|
|
|
0 |
Phenols Spec-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Other; Phenol + p-cresol + o-cresol + m-cresol; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.21 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 49107-6 |
Rubella virus Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Rubella virus IgM Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
49107-6 |
|
|
|
|
Both |
|
|
|
0 |
RUBV IgM Titr Ser |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Congenital rubella syndrome; Dilution factor; Dilution Factor (Titer); German measles; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; RUBV; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.21 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 49108-4 |
Titanium |
MCnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
Titanium [Mass/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
DRUG/TOX |
|
49108-4 |
|
|
|
|
Both |
|
|
|
0 |
Titanium Spec-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Misc; Miscellaneous; Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; TI; To be specified in another part of the message; Unspecified |
2.73 |
2.21 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 49109-2 |
Toxoplasma gondii Ab |
ACnc |
CSF |
Pt |
Qn |
IA |
|
ACTIVE |
Toxoplasma gondii Ab [Units/volume] in Cerebral spinal fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
MICRO |
|
49109-2 |
|
IA |
|
|
Both |
|
|
|
0 |
T gondii Ab CSF IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Neuro; Neurology; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SUDS; T gondii; Toxo; Toxoplasmosis |
2.73 |
2.21 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4911-4 |
HLA-Dw5 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-Dw5 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4911-4 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-Dw5 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49110-0 |
Mycoplasma sp |
Prid |
Urine |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Mycoplasma sp identified in Urine by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49110-0 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Mycoplasma Ur Cult |
|
|
|
N |
|
C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Myco; Mycoplas; Mycoplasm; Mycoplasmosis; Mycoplsm; Nominal; Point in time; Random; Spec; species; spp; UA; UR; Urn |
2.79 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 49111-8 |
Spermatozoa |
Naric |
Urine sed |
Pt |
Qn |
Microscopy.light.HPF |
|
ACTIVE |
Spermatozoa [#/area] in Urine sediment by Microscopy high power field |
|
MIN |
DefinitionDescription |
|
|
/HPF |
|
|
|
|
|
|
UA |
|
49111-8 |
|
Microscopy.light.HPF |
|
|
Observation |
|
|
|
0 |
Sperm #/area UrnS HPF |
|
|
|
N |
|
#/area; Kidney; LM; Micro; Micros; Microscopic; Nephrology; Number areic; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; Sperm; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS |
2.73 |
2.21 |
|
|
|
|
|
|
|
/[HPF] |
|
|
|
0 |
| 49112-6 |
Borna disease virus Ab |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Borna disease virus Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49112-6 |
|
|
|
|
Both |
|
|
|
0 |
Borna DV Ab Ser-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; BDV; Borna DV; Dis; Diseases; Dz; ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.69 |
2.21 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 49113-4 |
ZAP70 Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
ZAP70 Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
49113-4 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
ZAP70 Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified; ZAP-70; Zeta-associated protein 70 |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49114-2 |
Flavivirus rRNA |
ACnc |
Bld |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Flavivirus rRNA [Units/volume] (viral load) in Blood by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
MICRO |
|
49114-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Flavivirus rRNA Bld NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Blood; DNA NUCLEIC ACID PROBE; DNA probe; Flavi virus; Gen-Probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; ribosomal RNA; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load; WB; Whole blood |
2.68 |
2.21 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
